Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of Intravenous Selonabant in Healthy Adults
NCT07211607Phase 1Completed
- Sponsor
- Anebulo Pharmaceuticals
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of drinabant in Acute cannabinoid intoxication (ACI) (5 cohorts), sponsored by Anebulo Pharmaceuticals. Primary endpoints: Number of Participants with Adverse Events at 28 days, Number of Participants with Clinically Significant Laboratory Test Results at 28 days and 9 more. Started Sep 2025; status: completed.
02
Drugs
drinabant
03
Conditions
Acute cannabinoid intoxication (ACI)
Beyond the preview
Go deeper on NCT07211607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07211607.